Preclinical
With COVID-19 resurging in the U.S., particularly in states with the lowest vaccination rates, additional news and research about the vaccines and the virus is coming out. Here’s a look.
Companies such as Indoor Biotechnologies in Virginia are leveraging cutting-edge scientific techniques to knock out the Fel d 1 protein completely from the cats.
Preclinical data for its drug candidate, LP-184, reportedly showed over 90 percent efficacy in shrinking pancreatic cancer tumors in mouse models in vitro, in-vivo, and ex-vivo.
The randomized, multi-center study called CheckMate -651 evaluates Opdivo 3 mg/kg every two weeks in combination with Yervoy 1mg/kg every six weeks.
The drug, a novel dopamine D3-receptor antagonist, is being evaluated in Phase IIb trials for people with Parkinson’s disease who experience levodopa-induced dyskinesia.
The device is at the core of the BRAVO trial, which evaluates signals to control complex devices for motor and speech in adults who have been severely affected by neurological disorders.
The vaccine candidate ASP3772 generated an antibody response to each of the 24 polysaccharides in its makeup and antibody response to the two conserved pneumococcal proteins.
The company said that it values the FDA’s feedback and is happy that the agency has accepted its request to provide insights on its Hepatitis B development program.
University of Oxford researchers have begun clinical trials for a new vaccine that can potentially target a wide range of HIV variants.
Orphazyme said that its OLE trial, which has been running for the past 24 months, showed that arimoclomol could be an effective and safe option in treating Niemann-Pick disease type C.
PRESS RELEASES